Receptor activator of nuclear factor κB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening
- 1 October 2003
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Rheumatology
- Vol. 32 (5), 287-294
- https://doi.org/10.1080/03009740310003929
Abstract
Objective: The pathogenesis of periprosthetic bone loss in aseptic and septic prosthesis loosening is unclear. There is considerable evidence that macrophages and osteoclasts play a key role in focal bone erosion and osteolysis around the prosthesis. RANKL (receptor activator of nuclear factor κB ligand) was shown to be a potent osteoclastogenic factor, and to be involved in bone destruction of myeloma and rheumatoid arthritis patients. Osteoprotegerin (OPG) is the natural RANKL inhibitor and may prevent periprosthetic bone loss. Methods: The presence and distribution of RANKL, its receptor RANK and OPG in the periprosthetic interface of septically (n=5) and aseptically (n=6) loosened prostheses was examined by immunohistochemistry and immunoblotting. Additionally, the immunophenotype of the inflammatory infiltrate was determined [CD3, CD68, Ki‐67, tartrate‐resistant acid posphatase (TRAP)]. Results: Aseptic and septic cases revealed a different histopathologic pattern. However, in all cases RANKL and RANK could be demonstrated in macrophages and giant cells. In addition, RANKL detected by immunoblot analysis proved to have the same molecular weight as a recombinant RANKL used as a control (31 kD and approximately 48 kD). OPG was detected in aseptic loosening, where macrophages showed a strong staining, but multinucleated giant cells were only weakly stained. A weak OPG staining was also observed in septic loosening. Conclusion: The pathogenesis of bone loss in septic loosening remains unclear, because the septic membrane bears few macrophages and giant cells, and half of them express OPG. In aseptic loosening, macrophages might not be stimulated by RANKL as a result of OPG expression. But multinucleated giant cells may be activated, as they hardly express OPG. They might be responsible for periprosthetic bone loss in aseptic loosening as a result of their RANKL and RANK expression.Keywords
This publication has 16 references indexed in Scilit:
- Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controlsRheumatology, 2003
- Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysisJournal of Orthopaedic Research, 2002
- Twenty-five-Year Survivorship of Two Thousand Consecutive Primary Charnley Total Hip ReplacementsThe Journal of Bone and Joint Surgery-American Volume, 2002
- Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cellsAnnals Of The Rheumatic Diseases, 2002
- The osteoprotegerin/receptor activator of nuclear factor ?B/receptor activator of nuclear factor ?B ligand system in cartilageArthritis & Rheumatism, 2001
- Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patientsArthritis & Rheumatism, 2001
- Correlation of synovial fluid cytokine levels with histological and clinical parameters of primary and revision total hip and total knee replacementsActa Orthopaedica, 2001
- Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophagesAnnals Of The Rheumatic Diseases, 2000
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Reactions of the articular capsule to wear products of artificial joint prosthesesJournal of Biomedical Materials Research, 1977